Pharmasset Reports Preliminary Results Of A 4-week Combination Study Of R7128 For The Treatment Of Chronic Hepatitis C

Pharmasset, Inc.
(Nasdaq: VRUS) announces the preliminary results of the third cohort of a
4-week Phase 1 clinical trial evaluating R7128 1000mg twice daily (BID) in
combination with the standard of care (SOC), Pegasys(R) (pegylated
interferon) plus Copegus(R) (ribavirin), in 31 treatment-naive patients
chronically infected with hepatitis C virus (HCV) genotype 1. R7128, a
prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of HCV
that is being developed in collaboration with Roche.



As previously reported for Cohorts 1 and 2 of this study, R7128 has
demonstrated potent short-term antiviral activity and was generally safe
and well tolerated at doses of 500mg and 1500mg administered for 28 days in
combination with SOC. In Cohort 3, a new formulation of R7128 1000mg BID
was administered in combination with SOC. Of the 31 patients enrolled, 25
patients received R7128 1000mg BID and 6 received placebo. 88% (22 of 25)
patients receiving R7128 1000mg BID with SOC for 4 weeks achieved
undetectable HCV RNA levels (Buy Diflucan Without Prescription